Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods of preventing or treating T cell malignancies by administering CD2 antagonists

A technology of malignant tumors and antagonists, applied in the direction of antibodies, etc.

Inactive Publication Date: 2006-05-10
IMMUNOMEDICS INC +1
View PDF215 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Also, it is unusual for cancer to be treated with only one approach

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of preventing or treating T cell malignancies by administering CD2 antagonists
  • Methods of preventing or treating T cell malignancies by administering CD2 antagonists
  • Methods of preventing or treating T cell malignancies by administering CD2 antagonists

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0087] The present invention includes treatment protocols that provide a better prevention or treatment profile than current single agent or combination therapies for cancer, especially T-cell malignancies, or one or more symptoms thereof. The present invention provides CD2 antagonist-based therapies to prevent, treat, treat, or improve cancer, especially T-cell malignancies, or one or more symptoms thereof. Specifically, the present invention provides a prevention and treatment plan to prevent, treat, treat, or ameliorate cancer, especially T-cell malignancies, or one or more of its symptoms. The plan includes administering MEDI-507 to patients in need of treatment. , Its analogs, derivatives or antigenic fragments.

[0088] The present invention also provides pharmaceutical compositions and kits containing CD2 antagonists for preventing, treating, treating, or improving cancer, especially T-cell malignant tumors, or one or more symptoms thereof. Specifically, the present inventi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention includes the use of CD2 antagonists, preferably MEDI-507, its analogs, derivatives or antigen-binding fragments as a single agent therapy to prevent, treat, treat or ameliorate cancer, especially T-cell malignancies, or one of them or multiple symptoms. The present invention also includes the use of a CD2 antagonist, preferably MEDI-507, an analogue, derivative or antigen-binding fragment thereof in combination with other cancer treatments. The present invention also provides a pharmaceutical composition containing a CD2 antagonist, preferably MEDI-507, its analogue, derivative or antigen-binding fragment, and the amount of the contained CD2 antagonist can effectively prevent, treat, treat or improve cancer, especially T-cell malignancies, or one or more symptoms thereof.

Description

[0001] This application claims the priority of U.S. Provisional Patent Application No. 60 / 409,024 filed on September 5, 2002 and U.S. Provisional Patent Application No. 60 / 410,385 filed on September 12, 2002, both of which are fully incorporated herein as reference. 1. Field of Invention [0002] The present invention includes the use of CD2 antagonists, preferably MEDI-507, analogs, derivatives or antigen-binding fragments thereof as single-agent therapy to treat, prevent, treat or ameliorate cancer, especially T-cell malignancies, or one of them One or more symptoms. The present invention also includes the use of CD2 antagonists, preferably MEDI-507, its analogs, derivatives or antigen-binding fragments, in combination with other cancer treatments. The present invention also provides a pharmaceutical composition containing a CD2 antagonist, preferably MEDI-507, its analogs, derivatives or antigen-binding fragments. The amount of the CD2 antagonist contained can effectively preven...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/395
Inventor C·丁吉万T·沃尔德曼Z·张M·张
Owner IMMUNOMEDICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com